Study on itraconazole vs griseofulvin in treatment of tinea.

Comparative study on efficacy of oral ultramicrosized Griseofulvin and Itraconazole on dermatophytic infection of skin - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061906

Enrollment

240

Registered

2024-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Dr.Amarjeet: junior resident Intervention2: Ultramicrosized Griseofulvin: Anti-fungal drug - Dose: 500 mg - Frequency: Twice Daily - Route: Oral - Follow up at 2 weeks, 4 weeks, 6 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Freshly diagnosed patients of age 18 years and above with clinical diagnosis of tinea corporis and tinea cruris confirmed by potassium hydroxide (KOH) test attending the dermatology OPD at ELMC&H.

Exclusion criteria

Exclusion criteria: Previously treated patient within 3 months.Patients with pre-existing renal disease, hepatic disease and cardiac disease.Pregnant & lactating women

Design outcomes

Primary

Measure	Time frame
To observe the efficacy of oral Itraconazole and Ultramicrosized Griseofulvin in dermatophytic infection. Timepoint: 0,2,4 and 8 weeks	—

Secondary

Measure	Time frame
To study the clinical response of dermatophytic infection to oral Itraconazole. To study the clinical response of dermatophytic infection to oral Ultramicrosized GriseofulvinTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactAmarjeet

ERA lucknow medical college

drkshitijsaxena@live.com9208015391

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026